Biocon Biologics

Biocon Biologics Secures U.S. Market Entry Date for Bosaya and Aukelso, Denosumab Biosimilars

1 October 2025 -- Bengaluru, India and New Jersey, US -- Biocon Biologics Ltd, a fully integrated global biosimilars company and subsidiary of Biocon Ltd, today announced a settlement and license agreement with Amgen Inc. that clears the path for the commercialization of Bosaya (denosumab-kyqq) and Aukelso (denosumab-kyqq) in the United States. Bosaya 60 mg/mL...

Biocon Biologics Successfully Completes Integration of Viatris’ Biosimilar Business in 31 Countries in Europe

30 November 2023 -- Bengaluru, India -- Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd, today announced that the integration of the Viatris’ biosimilars business in 31 European countries has been successfully completed. Following the acquisition of substantially all of the global biosimilar business of Viatris in November 2022, and the related integration of over 70 emerging market countries...
Biocon House, Semicon Park Electronics City, Phase – II, Hosur Road Bengaluru 560100, Karnataka, India

91 80 6775 6775